“Ongoing Human Evolution Could Explain Recent Rise in Certain Disorders - Science Daily” plus 4 more |
- Ongoing Human Evolution Could Explain Recent Rise in Certain Disorders - Science Daily
- Molecular Security System Protects Cells From Potentially Harmful DNA - Redorbit.com
- Nu Skin Announces New Scientific Advisor - NPI center
- Nu Skin Appoints New Scientific Advisor - Happi
- DiscoveRx Corp. & Jubilant Biosys Limited Announce Co-Marketing ... - Yahoo Finance
Ongoing Human Evolution Could Explain Recent Rise in Certain Disorders - Science Daily Posted: 11 Jan 2010 07:59 AM PST ScienceDaily (Jan. 11, 2010) The subtle but ongoing pressures of human evolution could explain the seeming rise of disorders such as autism, autoimmune diseases, and reproductive cancers, researchers write in the Proceedings of the National Academy of Sciences. Certain adaptations that once benefited humans may now be helping such ailments persist in spite of -- or perhaps because of -- advancements in modern culture and medicine. "This work points out linkages within the plethora of new information in human genetics and the implications for human biology and public health, and also illustrates how one could teach these perspectives in medical and premedical curricula," says author Peter Ellison, John Cowles Professor of Anthropology at Harvard University. Ellison's co-authors are Stephen Stearns of Yale University, Randolph Nesse of the University of Michigan, and Diddahally Govindaraju of the Boston University School of Medicine. The research was first presented at the Arthur M. Sackler Colloquium, co-sponsored by the National Academy of Science and the Institute of Medicine. Colloquium presentations described in the current paper include research suggesting that:
In the final presentation of the colloquium, researchers called for the integration of evolutionary perspectives into medical school curricula, to help future physicians consider health problems from an evolutionary perspective. "We're trying to design ways to educate physicians who will have a broader perspective and not think of the human body as a perfectly designed machine," says Ellison. "Our biology is the result of many of evolutionary trade-offs, and understanding these histories and conflicts can really help the physician understand why we get sick and what we might do to stay healthy." Previous work in evolutionary medicine helped explain why disease is so prevalent and difficult to prevent -- because natural selection favors reproduction over health, biology evolves more slowly than culture, and pathogens evolve more quickly than humans. "I think that the main take-home point is that evolution and medicine really do have things to say to each other, and some of these insights actually reduce suffering and save lives," says Stearns. Story Source: Adapted from materials provided by Harvard University, via EurekAlert!, a service of AAAS. Journal Reference:
Note: If no author is given, the source is cited instead. Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. | |
Molecular Security System Protects Cells From Potentially Harmful DNA - Redorbit.com Posted: 11 Jan 2010 05:50 AM PST Posted on: Monday, 11 January 2010, 07:55 CST U of Minnesota researcher leads study Researchers at the University of Minnesota have discovered a molecular security system in human cells that deactivates and degrades foreign DNA. This discovery could open the door to major improvements in genetic engineering and gene therapy technologies. Led by Reuben Harris, associate professor of biochemistry, molecular biology and biophysics in the College of Biological Sciences, the report's findings was published online by Nature Structural and Molecular Biology on Jan. 10. In the study, Harris and colleagues show how APOBEC3A, an enzyme found in human immune cells, disables double-stranded foreign DNA by changing cytosines (one of the four main bases in DNA) to uracils (an atypical DNA base). Persisting DNA uracils result in mutations that disable the DNA. In addition, the authors show that other enzymes step in to degrade the uracil-containing foreign DNA and sweep its remains out of the cell. "Scientists have known for a long time that some human cells take up DNA better than others, but we haven't had good molecular explanations," Harris says. "This is definitely one of the reasons. Foreign DNA restriction is a fundamental process that could have broad implications for a variety of genetic diseases." By understanding how the mechanism works, scientists can develop ways to manipulate it to enable more effective methods to swap bad genes for good ones. Harris is also intrigued to learn why the mechanism doesn't affect a cell's own DNA. The discovery of an analogous foreign DNA restriction mechanism in bacteria launched the field of genetic engineering during the 1970s. Once bacterial DNA restriction enzymes were understood, their power was harnessed to cut and paste segments of DNA for a wide variety of therapeutic and industrial purposes. College of Biological Sciences (CBS) faculty conduct research in all areas of biology, from molecules to ecosystems, which supports applications in medicine, renewable energy, agriculture and biotechnology. The college offers degree programs in biochemistry, molecular biology and biophysics; genetics, cell biology and development; ecology, evolution and (animal) behavior; plant biology; microbiology and neurosciences. Admission to undergraduate and graduate programs is highly competitive. --- On the Net: Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. | |
Nu Skin Announces New Scientific Advisor - NPI center Posted: 11 Jan 2010 06:47 AM PST Nu Skin Announces New Scientific Advisor
PROVO, Utah, Jan 11, 2010 /PRNewswire via COMTEX/ -- Nu Skin Enterprises, Inc., a premier anti-aging company, announced Stuart Kim, Ph.D., professor at Stanford University in the departments of Developmental Biology and Genetics, as a new member of the Nu Skin Anti-Aging Scientific Advisory Board. Dr. Kim will provide insights on the molecular analysis of aging science. "We are honored to welcome Dr. Kim to the Nu Skin Anti-Aging Scientific Advisory Board and believe that our collaboration with him will increase our scientific efforts to target the sources of aging," said Joseph Chang, Ph.D., Nu Skin chief scientific officer and executive vice president of product development. "Dr. Kim has spent much of his career studying the genetic basis of aging and has garnered significant attention in the scientific community related to his identification of an important gene that could play a critical role in aging. This important work will add to the further understanding of the molecular mechanism by which certain proteins regulate aging." Kim received bachelors' degrees in chemistry and philosophy from Dartmouth College in 1979. Dr. Kim then moved to biology at Caltech and received a doctorate in 1984. He spent five years as a post-doctoral fellow at MIT and is currently a professor in the departments of Developmental Biology and Genetics at Stanford University, as well as a faculty affiliate to the Stanford Center on Longevity. Kim's recent research interests have focused on functional genomics and systems biology. He has produced DNA microarrays for C. elegans and used them to profile gene expression during development and aging. He has also assembled large sets of data from microarray experiments, and used them to find sets of co-regulated genes acting as genetic modules. His developmental drift theory of aging has been published in the scientific journal Cell. Before working on functional genomics, Kim worked on cell polarity in epithelial cells and Ras signaling in C. elegans. Dr. Kim has been a Markey Scholar, a Searle Scholar and an Ellison Scholar for his research on the genetics of aging. He is an editor of PLOS Genetics, on the National Science Advisory Council for the American Federation for Aging Research and the Scientific Advisory Board for the Buck Institute for Age Research. Nu Skin Anti- Aging Scientific Advisory Board Several highly distinguished scientific advisors representing top research and learning institutions around the world combine to form Nu Skin's Anti-Aging Scientific Advisory Board. Nu Skin has brought together leaders in aging, genetics, developmental biology, dermatology and nutrition and the company benefits from their knowledge and experience as it seeks to demonstrate the Nu Skin difference by remaining at the forefront of scientific knowledge and product development. Other scientific advisors include Richard Weindruch, Ph.D., Tomas Prolla, Ph.D., and Zoe Draelos, M.D. The Company Nu Skin Enterprises, Inc. demonstrates innovation through its comprehensive anti-aging product portfolio, independent business opportunity and corporate social responsibility initiatives. Nu Skin's scientific leadership in both skin care and nutrition has established Nu Skin as a premier anti-aging company, evidenced in its unique ageLOC(TM) science that addresses aging at its source. The company's anti-aging products feature the new ageLOC daily skin care system and Future Serum, as well as the Galvanic Spa(R) System II, Tru Face(R) Essence Ultra, LifePak(R) Nano and the g3 nutrition beverage. A global direct selling company, Nu Skin operates in 48 markets worldwide and has more than 750,000 independent sales representatives. Nu Skin is traded on the New York Stock Exchange under the symbol "NUS." More information is available at http://www.nuskin.com. Please note: This press release contains forward-looking statements that represent the company's current expectations and beliefs which involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. The forward-looking statements contained herein are qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission, including the company's most recent Form 10-K and Forms 10-Q. Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. | |
Nu Skin Appoints New Scientific Advisor - Happi Posted: 11 Jan 2010 06:33 AM PST Nu Skin Enterprises, Inc.tapped Stuart Kim, Ph.D., professor at Stanford University in the departments of Developmental Biology and Genetics, as its newest member of the Nu Skin Anti-Aging Scientific Advisory Board. According to the company, Dr. Kim will provide insights on the molecular analysis of aging science. "We are honored to welcome Dr. Kim to the Nu Skin Anti-Aging Scientific Advisory Board and believe that our collaboration with him will increase our scientific efforts to target the sources of aging," said Joseph Chang, Ph.D., Nu Skin chief scientific officer and executive vice president of product development. "Dr. Kim has spent much of his career studying the genetic basis of aging and has garnered significant attention in the scientific community related to his identification of an important gene that could play a critical role in aging. This important work will add to the further understanding of the molecular mechanism by which certain proteins regulate aging." Kim received bachelors' degrees in chemistry and philosophy from Dartmouth College in 1979. He then moved to biology at Caltech and received a doctorate in 1984. He spent five years as a post-doctoral fellow at MIT and is currently a professor in the departments of Developmental Biology and Genetics at Stanford University, as well as a faculty affiliate to the Stanford Center on Longevity. Kim's recent research interests have focused on functional genomics and systems biology. He has been a Markey Scholar, a Searle Scholar and an Ellison Scholar for his research on the genetics of aging.
Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. | |
DiscoveRx Corp. & Jubilant Biosys Limited Announce Co-Marketing ... - Yahoo Finance Posted: 11 Jan 2010 07:23 AM PST BANGALORE, India, January 11 /PRNewswire-FirstCall/ -- Jubilant Biosys Limited, based in Bangalore, an integrated Drug Discovery and Development solution provider, a subsidiary of Jubilant Organosys Ltd, headquartered in Noida, announced today that it has entered into a co-marketing agreement to provide screening solutions, with DiscoveRx Corporation (Fermont, USA), a premier provider of innovative cell based assay solutions for GPCR, Kinases, NHR and Proteases. This agreement allows Jubilant access to DiscoveRx PathHunter(TM) and cAMPHunter(TM) cell lines and proprietary EFC chemiluminescent detection technology to perform screening on behalf of Jubilant's customers. The agreement also enables DiscoveRx to expand its platform technology to offer screening solutions from India. DiscoveRx's PathHunter(TM) ss-Arrestin and HitHunter(TM) cAMP assays are homogeneous chemiluminescent assays which are rapidly becoming GPCR screening platform of choice for screening and profiling applications. Jubilant's demonstrated capabilities in discovery research state of the art medicinal chemistry, modeling, structural biology and screening facilities including High Throughput screening facility supported by automated compound management and visualization tools coupled with the DiscoveRx award winning assay platform offers global pharmaceutical companies access to cost effective screening and lead generation services that will enable and accelerate global drug discovery efforts. Commenting on the Collaboration, Dr. Kailash Swarna, COO, Global Drug Discovery, at Jubilant Biosys said: "We are pleased to announce this agreement with DiscoveRx, and look forward to the prospect of providing value to our customers using DiscoveRx PathHunter(TM) and HitHunter(TM) technologies. This partnership continues to demonstrate Jubilant's mission to partner with leading technology providers that provide access to cutting edge and innovative solutions to accelerate global drug discovery efforts with our collaborators." Pyare Khanna, President and CEO, DiscoveRx Corporation says, "DiscoveRx constantly strives to provide our truly innovative solutions to screening community. We are determined to help expedite the drug discovery processes and are delighted with this relationship with Jubilant. Our customers require an easy access to our innovative product portfolio and such partnerships will add value to our efforts of bringing industry leading portfolio of PathHunter(TM) and HitHunter(TM) GPCR assays to a broader audience." About DiscoveRx Corporation Founded in 2000, DiscoveRx is a privately held, venture-backed company headquartered in Fremont, California, with an additional office in Birmingham, England. The Company pioneered the use of B-galactosidase enzyme fragment complementation in biochemical and cell based assays for discovery research, and holds extensive intellectual property in this area. DiscoveRx is dedicated to the development and commercialization of innovative solutions to study GPCRs, Kinases and other major drug target classes, and many of their innovative products have been widely adopted in pharmaceutical and biotech drug screening laboratories worldwide. The Company is also a recipient of two Frost and Sullivan 2008 awards: Award for Innovation in North American Healthcare Market as well as a European Product Line Strategy Award for it's GPCR Cell Based assay portfolio. For more information on DiscoveRx products, please visit http://www.discoverx.com. About Jubilant Biosys: Jubilant Biosys Ltd., a subsidiary of Jubilant Organsys Ltd., provides integrated drug discovery and development solutions to the global pharmaceutical industry. Jubilant Biosys has an integrated state of the art facility in Bangalore. The Center houses over 450 scientists specializing in multiple disciplines to include Discovery biology, medicinal chemistry, structural biology, pharmacology, toxicology, pharmacy chem., molecular modeling, crystallography and information technology supporting discovery efforts. For more information please visit: http://www.jubilantbiosys.com Contacts: DiscoveRx Corporation Sailaja Kuchibhatla Sr. VP Business Development DiscoveRx Corp. skuchibhatla@discoverx.com +1-510-979-1415 ext. 104 Jubilant Biosys Ltd. Esha Kakkar Executive - Corporate Planning Jubilant Biosys Ltd. Ph: +91-80-66628683 esha_kakkar@jubilantbiosys.com Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
You are subscribed to email updates from Biology - Bing News To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
Google Inc., 20 West Kinzie, Chicago IL USA 60610 |
0 comments:
Post a Comment